Brokerages Set Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) PT at $37.33

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have received an average rating of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $37.3333.

A number of equities research analysts have recently commented on NBTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Leerink Partners boosted their price target on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, June 4th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th.

Nanobiotix Price Performance

Shares of Nanobiotix stock opened at $41.67 on Thursday. Nanobiotix has a 1 year low of $8.03 and a 1 year high of $57.14. The company’s fifty day moving average is $39.55 and its two-hundred day moving average is $36.52.

Institutional Investors Weigh In On Nanobiotix

Several large investors have recently modified their holdings of NBTX. Royal Bank of Canada raised its position in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after buying an additional 2,500 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Nanobiotix in the fourth quarter valued at about $220,000. Finally, Millennium Management LLC purchased a new stake in shares of Nanobiotix in the fourth quarter valued at about $390,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.